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Acinetobacter baumannii (A. baumannii ) is a Gram-negative, strictly aerobic, non-
fermentative coccobacillus, which is widely distributed in nature. Recently, it has emerged
as a major cause of health care-associated infections (HCAIs) in addition to its capacity
to cause community-acquired infections. Risk factors for A. baumannii infections and bac-
teremia in recipients of hematopoietic stem cell transplantation include: severe underlying
illness such as hematological malignancy, prolonged use of broad-spectrum antibiotics,
invasive instrumentation such as central venous catheters or endotracheal intubation,
colonization of respiratory, gastrointestinal, or urinary tracts in addition to severe immuno-
suppression caused by using corticosteroids for treating graft versus host disease. The
organism causes a wide spectrum of clinical manifestations, but serious complications
such as bacteremia, septic shock, ventilator-associated pneumonia, extensive soft tissue
necrosis, and rapidly progressive systemic infections that ultimately lead to multi-organ fail-
ure and death are prone to occur in severely immunocompromised hosts.The organism is
usually resistant to many antimicrobials including penicillins, cephalosporins, trimethoprim–
sulfamethoxazole, almost all fluoroquinolones, and most of the aminoglycosides. The
recently increasing resistance to carbapenems, colistin, and polymyxins is alarming. Addi-
tionally, there are geographic variations in the resistance patterns and several globally and
regionally resistant strains have already been described. Successful management of A.
baumannii infections depends upon appropriate utilization of antibiotics and strict applica-
tion of preventive and infection control measures. In uncomplicated infections, the use of a
single active beta-lactam may be justified, while definitive treatment of complicated infec-
tions in critically ill individuals may require drug combinations such as colistin and rifampicin
or colistin and carbapenem. Mortality rates in patients having bacteremia or septic shock
may reach 70%. Good prognosis is associated with presence of local infection, absence of
multidrug resistant strain, and presence of uncomplicated infection while poor outcome is
associated with severe underlying medical illness, bacteremia, septic shock, multi-organ
failure, HCAIs, admission to intensive care facilities for higher levels of care, and culture of
certain aggressive genotypes of A. baumannii.
Keywords: Acinetobacter baumannii, hematological malignancy, hematopoietic stem cell transplantation,
virulence, drug resistance
OVERVIEW OF ACINETOBACTER BAUMANNII INFECTIONS
INTRODUCTION
Acinetobacter baumannii (A. baumannii) is a Gram-negative,
strictly aerobic, non-fastidious, non-motile, catalase-positive,
oxidase-negative, and non-fermentative coccobacillus. It is widely
distributed in nature and environmental sources include: soil,
water, vegetables, animals, and insects (1–3). The genus Acine-
tobacter comprises more than 30 different species. The four most
common pathogenic types in humans are: A. baumannii, A. cal-
coaceticus, Acinetobacter genomic species 3, and Acinetobacter
genomic species 13TU. These four species are very closely related
and are difficult to be distinguished from each other by phenotypic
properties (1–3). In 1911, Willem Beijerinck isolated an organism
named Micrococcus calcoaceticus from soil after enrichment in a
calcium-acetate-containing medium. The genus designation was
initially proposed by Brisou and Prevot in 1954 then by Bauman
et al in 1968. In the year 1974, the genus was finally listed in
Bergey’s manual of clinical bacteriology and a single species, A.
calcoaceticus, was described (1, 2).
SOURCES OF INFECTIONS AND VIRULENCE
Sources of A. baumannii infections include: skin and mucous
membranes, burns and wounds, intravascular and urinary
catheters, as well as gastrointestinal, urinary, and respiratory tracts.
However, at times no source of infection or bacteremia can be iden-
tified (1, 3). Hospital sources of infection include: sinks, tables,
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mattresses, pillows, shower units, infusion pumps in addition to
suction and resuscitation equipment (4).
The bacterium harbors a number of effective virulence factors
that include: (1) attachment to and persistence on solid and dry
surfaces, (2) ability to obtain nutrients such as iron, (3) adhesion
and subsequent destruction of epithelial cells, (4) ability of some
strains to produce gelatinases and proteinases that damage host
tissues, (5) ability to colonize the skin of patients as well as health
individuals without causing illness, and (6) ability to form biofilms
that play an important role in the process of colonization (2).
RISK FACTORS FOR A. BAUMANNII INFECTIONS
Acinetobacter baumannii causes colonization, various infectious
complications, and even epidemics. Community-acquired infec-
tions are less common than health care-associated infections
(HCAIs) (2–4). There are several risk factors for A. baumannii
infections and these are included in Table 1 (2–4).
CLINICAL ASPECTS OF A. BAUMANNII INFECTIONS
The clinical manifestations of A. baumannii infections are very
variable and include: non-specific features; soft tissue, skin,
and wound infections; urinary tract infections; gastrointesti-
nal tract (GIT) infections; respiratory tract infections includ-
ing community-acquired and hospital-acquired or ventilator-
associated pneumonia; infection of urinary or central venous
catheters (CVCs); eye infections including keratitis and endoph-
thalmitis; osteomyelitis; meningitis; endocarditis; and primary
bacteremia where no source of infection is found (1–3, 5, 6). Infec-
tions caused byA. baumannii can be complicated by: extensive soft
tissue necrosis, bloodstream infections, septic shock, acute respira-
tory distress syndrome (ARDS), disseminated intravascular coag-
ulation (DIC), systemic or disseminated infection, multi-organ
failure, and death (1, 3).
MANAGEMENT OF A. BAUMANNII INFECTIONS
A variety of tools are used in the diagnosis of A. baumannii infec-
tions. Swabs, septic screens, and surveillance cultures should be
Table 1 | Risk factors forA. baumanni i infections.
(1) Severe underlying illness, particularly hematological malignancy
(2) Critically ill patients admitted to ICU having endotracheal intubation
and high APACHE score
(3) Prolonged antimicrobial therapy with carbapenems, fluoroquinolones,
aminoglycosides, and third generation cephalosporins
(4) Infection or colonization of respiratory, urinary, and gastrointestinal
tracts
(5) Burns and surgical wounds
(6) Diabetes mellitus
(7) Chronic lung disease
(8) Blood product transfusions
(9) Enteral feeding and contaminated parenteral solutions
(10) Circumstances of hospitalization: length of stay, high work load, and
admission to wards with high density of infected or colonized patients
(11) Prematurity
ICU, intensive care unit; APACHE, acute physiology and chronic health evaluation.
taken from various sites. Blood cultures should be taken periph-
erally and centrally in patients having indwelling intravascular
catheters. Susceptibility studies and minimal inhibitory concen-
trations (MICs) should be performed on positive cultures. Mole-
cular methods such as polymerase chain reaction (PCR) are very
productive diagnostically. Radiological tools such as chest x-rays
and computed tomography (CT) scans of chest, abdomen, and
pelvis are helpful in determining the site of infection (5). A recent
systematic review and meta-analysis on the impact of antibi-
otic MIC on infection outcome in patients having susceptible
Gram-negative bacilli (GNB) revealed that there is an associ-
ation between high MIC values within the currently accepted
susceptible range and adverse outcome of infections caused by
Gram-negative organisms. Therefore, not only susceptibility data
but also MIC values are required to efficiently control infections
caused by GNB (7).
Treatment of A. baumannii infections includes the following:
(1) removal of vascular and urinary catheters, (2) surgical treat-
ment such as drainage of abscesses and debridement of wounds,
(3) use of appropriate antimicrobial agents, (4) growth factors
in neutropenic patients, (5) ICU admission and mechanical ven-
tilation may be required, and (6) transfusion of blood products
in cytopenic patients (3). The drug of choice for treatment of A.
baumannii infections is not yet established, so prospective and
randomized controlled are needed (1, 3, 6, 8, 9). The most effec-
tive drugs in treating A. baumannii infections are: carbapenems
such as imipenem and meropenem, β-lactam inhibitors such as
ampicillin–sulbactam in addition to piperacillin–tazobactam and
cephalosporins such as ceftazidime (1, 3, 6, 8, 9). For community-
acquired A. baumannii (CAAB) infections, the following antibi-
otics have been reported to be effective: cephalosporins such as cef-
tazidime,cefepime and cefpirome; carbapenems; aminoglycosides;
and fluoroquinolones (3).
New treatment options for A. baumannii infections include:
(1) polypeptide antibiotics such as colistin, polymyxin B, and
polymyxin E, (2) minocycline derivatives such as tigecycline, (3)
new carbapenems such as doripenem, and (4) new generation
cephalosporins such as ceftobiprole and ceftaroline (1, 3, 6, 8,
9). New experimental trials are needed to evaluate the activity
and safety of peptides and other novel antimicrobial agents for
A. baumannii infections (1, 3, 6, 8, 9). Treatment of complicated
infections in severely ill and septic patients having A. bauman-
nii is usually in the form of combination therapies that include:
piperacillin–tazobactam and amikacin, piperacillin–tazobactam
and colistin, or colistin and rifampicin (10).
Tigecycline is a first-in-class extended-broad-spectrum glycyl-
cycline that has activity against many Gram-positive and Gram-
negative organisms (11, 12). It overcomes the two key tetracycline
resistance mechanisms, efflux pump, and ribosomal protection,
and is unaffected by other bacterial mechanisms of resistance such
as extended-spectrum β-lactamases (ESBL). Unfortunately, the
use of tigecycline monotherapy has been associated with increased
mortality, adverse effects, and emergence of drug resistant isolates
(11, 12). However, tigecycline is still reserved as a last-resort drug
in the treatment of severe and complicated infections caused by
A. baumannii (12, 13). Data regarding the clinical use of tigecy-
cline in the treatment of Acinetobacter species are scarce and are
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confounded by the use of the drug in combination regimens. Also,
the potential development of resistance to tigecycline during the
course of therapy is of a concern (14). Although tigecycline has
shown considerable, though not consistent, antimicrobial activity
against multidrug resistant (MDR, including carbapenem resis-
tant) Acinetobacter species, the ultimate role of tigecycline in
the treatment of MDR Acinetobacter species remains undefined
(13–15). Therefore, well designed studies on the clinical use of tige-
cycline in the treatment of infections caused by MDRAcinetobacter
species are warranted (14).
Polymyxins such as colistin can be also used as last-resort drugs
in severe infections caused byA. baumannii (16). However, studies
have shown that colistin monotherapy is unable to prevent resis-
tance and does not influence the 30-day mortality in patients with
MDR A. baumannii (MDRAB) bloodstream infections (17, 18).
Therefore, combination therapy such as colistin and rifampicin or
colistin and carbapenem may be the best antimicrobial strategy
against colistin resistant A. baumannii infections (17).
PREVENTION OF A. BAUMANNII INFECTIONS
Decreasing the incidence of A. baumannii infections can be
achieved by applying the following preventive measures: (1) strict
infection control and contact precaution policies, (2) appropri-
ate use of invasive procedures, and (3) appropriate utilization of
antimicrobial agents (2, 3, 5, 8). Spread of MDRAB can be lim-
ited by: (1) enforcement of aggressive infection control measures,
(2) development of innovative control strategies, (3) education of
staff, patients, and visitors, (4) hand washing and use of antisep-
tics, (5) surveillance cultures from patients, staff, and environment,
and (6) cleaning and disinfection of hospital equipment (2, 3,
5, 8). Eradication of Acinetobacter species requires adherence to
good infection control practices, prudent antibiotic utilization,
and effective antimicrobial therapy (2, 3, 5, 8).
PROGNOSIS OF A. BAUMANNII INFECTIONS
The prognosis of A. baumannii infections varies considerably.
Good prognostic factors include: local infection or trauma,
absence of MDR strains, medical conditions other than malig-
nancy or burns, and prompt as well as efficient antibiotic therapy
(3). Poor prognosis is associated with: age >65 years, underlying
medical condition being malignancy or burns, presence of viru-
lent or MDR strain, late or inappropriate antimicrobial therapy,
DIC or coagulopathy, bacteremia or septic shock, mechanical ven-
tilation, and rapidly progressive or ultimately fatal illness (3). In
patients having A. baumannii infections, high mortality rates are
associated with: pneumonia, bacteremia, and inappropriate med-
ical treatment. The ultimate outcome of A. baumannii infections
correlates well with: the type of underlying medical illness, pres-
ence or absence of polymicrobial bacteremia, and appropriate or
inappropriate antimicrobial therapy (3).
DRUG RESISTANCE EXHIBITED BY A. BAUMANNII
EMERGENCE OF DRUG RESISTANCE
Acinetobacter baumannii is characterized by frequent MDR due to
multiple mechanisms. Isolates of A. baumannii have shown high
levels of antimicrobial resistance, particularly to β-lactam agents
(3, 19). Antimicrobial resistance among Acinetobacter species has
substantially increased in the last decade. In a European survey,
resistance of A. baumannii rated number 5 among the evolving
bacterial resistance to antimicrobial therapy (3, 19). The patterns
of antimicrobial resistance exhibited by A. baumannii isolates
vary among distinct geographical regions, especially for noso-
comial isolates. Approximately 11% of nosocomial isolates of A.
baumannii are resistant to carbapenems (20).
GENETIC RESISTANCE
With the advent of whole-genome sequencing, important gains
in the insights of genetic complexity of A. baumannii have been
obtained (1). Its wide array of drug resistance determinants and its
ability to effectively regulate these according to selective environ-
mental pressures clearly demand respect. The global epidemiology
of A. baumannii is of a concern for widespread dissemination,
most often in a clonal manner within institutions, cities, and some-
times between countries (1). In patients with bacteremia caused
by A. baumannii, complex genotype 2 is associated with greater
resistance and higher mortality compared to other genospecies,
particularly genospecies 13 TU. In critically ill patients with A.
baumannii bacteremia, genospecies 2 is significantly associated
with pneumonia while genotype 13 TU is associated with primary
bacteremia (21).
MECHANISMS OF DRUG RESISTANCE
Acinetobacter baumannii has various mechanisms of resistance
for different classes of antimicrobials. Examples of mechanisms
of drug resistance to various classes of antibiotics are shown in
Table 2 (1, 22–27). MDR determinants as well as genetic determi-
nants of drug resistance for A. baumannii are shown in Table 3
(22, 24–27).
MDR A. BAUMANNII
Acinetobacter species possess a wide array of β-lactamases that
hydrolyze and confer resistance to penicillins, cephalosporins,
and carbapenems (3). MDR is defined as non-susceptibility
Table 2 | Mechanisms ofA. baumanni i drug resistance.
Class of antibiotic Mechanisms of resistance
(1) β-Lactams β-Lactamases
Outer membrane proteins
Efflux pumps
Altered penicillin-binding proteins
(2) Aminoglycosides Aminoglycoside modifying enzymes
Efflux pumps
Ribosomal [16S rRNA] methylation
(3) Quinolones Efflux pumps
Modification to target binding site
Genetic mutations such as gyrA and
parC
(4) Tetracyclines and glycylcyclines Multidrug efflux pumps
Tetracycline-specific efflux
Ribosomal protection
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Table 3 | Determinants of drug resistance inA. baumanni i .
Type of determinant Examples
1. Multidrug resistance
determinants
Weak permeability
Efflux systems
Enzymatic mechanisms that comprise
production of:
(A) β-Lactamases such as OXA-23
carbapenemase
(B) Arm A 16S rRNA methylase
2. Genetic determinants
of resistance
Genetic mutations such as gyrA and parC
Insertion sequences
Novel genetic elements such as
chromosomal resistance genetic islands
to at least three antimicrobials; such as ampicillin–sulbactam,
piperacillin–tazobactam, ceftazidime, imipenem, meropenem,
aminoglycosides, ciprofloxacin, aztreonam, and trimethoprim–
sulfamethoxazole; which are routinely tested in the clinical lab-
oratory and to which A. baumannii would have been expected to
be susceptible (22, 28, 29). Risk factors for evolution of MDRAB
infections include: (1) previous use of carbapenems and third
generation cephalosporins, (2) recent insertion of a CVC, (3)
endotracheal intubation and mechanical ventilation, (4) recovery
of A. baumannii from various sites, and (5) bacteremia caused by
other microorganisms (3, 28, 29). MDRAB infections carry a high
crude mortality rate and have a great impact on health care settings
as they are most frequently encountered in severely ill patients (3).
Several outbreaks of MDRAB have been reported in USA. The
Infectious Diseases Society of America has recently identified A.
baumannii as one of the six particularly problematic pathogens in
terms of antimicrobial susceptibility issues arising from resistance
(22). Sequence type 92 (ST92) and the associated clonal complex
92 represent the most sampled and widespread sequence types
and are known as European clone 2 and worldwide clonal lin-
eage 2. Three clonal complexes were initially described in Europe
then documented in North America, Asia, Africa, and Australia
(30). The coexistence of several resistance determinants may also
present a significant threat (24).
The potentially effective antimicrobial agents against MDRAB
infections include: carbapenems; aminoglycosides such as gentam-
icin and amikacin; tetracyclines such as doxycycline and minocy-
cline; sulbactam; colistin; and tigecyclines. However, drug com-
binations are preferable and, in particular, the combination of
carbapenems and colistin is becoming the treatment of choice
(3, 6, 22). Therapeutic options for MDRAB infections are limited
and there are no controlled trials to guide the therapeutic choice.
Therefore, well designed clinical studies are necessary to guide
clinicians on decisions regarding the best therapeutic option for
patients with MDRAB infections (3, 6, 22).
Ciclopirox, a topical antifungal agent that was developed
40 years ago, has multiple potential uses including treatment of
human immunodeficiency virus (HIV), enhancement of wound
healing in diabetics, and potential use in the treatment of multi-
ple myeloma. It has been found to be effective in the treatment
of MDRAB infections (31). Recently, a number of studies have
focused on non-antibiotic approaches that utilize novel mecha-
nisms of action to achieve antibacterial activity against MDR bac-
teria (32). Modern advances in phage therapy, iron chelation treat-
ment, antimicrobial peptides, prophylactic vaccination, photody-
namic therapy, and nitric oxide-based treatments have also shown
promising activity against MDRAB (32). The siderophore sulbac-
tam [BAL 30072] has shown promising in vitro activity against
MDRAB isolates harboring AmpC and OXA β-lactamases (33).
CARBAPENEM-RESISTANT A. BAUMANNII
The emergence of carbapenem-resistant A. baumannii (CRAB)
was first reported in USA in 1991 (34). CRAB has been linked to
point multations in porin channels from the outer membrance.
These point mutations alter bacterial targets of functions thus
decreasing the affinity for antimicrobial agents or upregulating
cellular functions by producing efflux pumps or other proteins
(3). Spread of CRAB in Asia has been linked to global clone 2
(GC2) and Aba R-4 type resistance islands (35, 36). CRAB has
also been attributed to the expression of β-lactamases; such as
OXA-23, OXA-24/40, and OXA-58; which inactivate carbapenems
(37). Outbreaks of CRAB infections in hospital settings illustrate
the important role of post-acute care facilities in dissemination of
MDR bacterial pathogens (37).
Although imipenem is the most active agent against A. bau-
mannii, resistance to imipenem is becoming increasingly com-
mon and hospital outbreaks of imipenem resistant MDRAB
(IR-MDRAB) have been increasingly reported since the early
1990s. Risk factors for the development of IR-MDRAB infection
include: previous ICU admission, exposure to third generation
cephalosporins, and use of carbapenems (3). The time at risk, the
period of time at risk for appearance of IR-MDRAB, is a very
important confounding factor to be adjusted because the prob-
ability of appearance increases with the length of time (3). The
best therapeutic approach for CRAB infection is to use colistin
in combination with tigecycline or cefoperazone–sulbactam or
piperacillin–tazobactam (38).
PANDRUG RESISTANCE OF A. BAUMANNII
Pandrug resistant A. baumannii (PDRAB) has emerged as an
important cause of both endemic HCAIs as well as epidemic
outbreaks (39). PDRAB infections are associated with high mor-
bidity and mortality. In addition, their treatment has high costs
due to the utilization of ICU facilities and potent antimicrobial
therapies (39). Isolates of PDRAB were first reported in 1998 in
Taiwan (34). PDRAB strains are usually resistant to all antibi-
otics that are routinely used including: ampicillin–sulbactam; cef-
tazidime and cefepime; piperacillin–tazobactam; aztreonam; flu-
oroquinolones including ciprofloxacin, travofloxacin, and moxi-
floxacin; garenoxacin as well as amikacin and carbapenems includ-
ing imipenem and meropenem (34, 40–42). The increased uti-
lization of carbapenems and fluoroquinolones as well as clonal
dissemination may explain the recent spread of PDRAB strains
(40–42).
The British Society of Antimicrobial Chemotherapy has pro-
vided criteria to designate MICs for tigecycline-susceptible-and-
resistant A. baumannii isolates as ≤1 and >2µg/ml, respectively.
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Implementation of these breakpoints would limit the use of tige-
cycline to salvage therapy for certain infections caused by PDRAB
(16). Novel therapies for PDRAB or extensively drug resistant
A. baumannii (XDRAB) infections include: (1) drug combina-
tions containing colistin or polymyxin B, which are composed of
two or three drugs including imipenem, rifampicin, amikacin, or
ampicillin–sulbactam in addition to colistin or polymyxin B and
(2) drug combinations that are composed of tigecycline in addition
to two other drugs including: imipenem, amikacin, and cefepime
(43, 44). Aggressive early treatment of PDRAB with adequate doses
of drugs in combinations such as carbapenem–sulbactam may
prevent the emergence of PDRAB strains (45). A multifaceted
approach or intervention that includes active surveillance, envi-
ronmental cleaning, and appropriate utilization of antimicrobials
appears to be efficient and cost–effective in the management of
PDRAB infections (39).
ACINETOBACTER BAUMANNII BACTEREMIA
SOURCES OF BACTEREMIA AND EPIDEMIOLOGY
Acinetobacter baumannii bacteremia may be primary, where no
cause is found, or secondary to infections involving wounds, res-
piratory, and urinary tracts in addition to other sites of infection
(1, 3). A. baumannii bloodstream infections are more common in
ICU settings than in general hospital wards and are more frequent
in hospitals than in the community. They usually develop at a mean
of 26 days from the time of hospital admission (1). In a large study
of nosocomial blood stream infections in the USA (1995–2002),A.
baumannii ranked the 10th most common etiological agent being
responsible for 1.3% of all monomicrobial bloodstream HCAIs
(1). However, only 62% of A. baumannii bacteremias in hospi-
talized patients are considered clinically significant. Therefore, it
is essential to perform thorough clinical evaluation of patients
to eliminate the possibility of pseudobacteremia (3). Additionally,
approximately 30% of patients withA. baumannii bacteremia have
polymicrobial bacteremia or other infections (3).
RISK FACTORS FOR A. BAUMANNII BACTEREMIA
There are several risk factors for the development of A. bauman-
nii bacteremia and these are shown in Table 4 (3, 29, 46). The
risk factors for mortality related to A. baumannii bacteremia are
variable and they include: (1) advanced age, (2) recent surgery,(3)
immunosuppressive status, (4) invasive procedures such as CVC,
urinary catheterization, pulmonary catheterization, mechanical
ventilation, and nasogastric tubes, (5) presence of complications
such as septic shock, DIC, acute renal failure, and acute respiratory
failure, (6) use of inappropriate antibiotic therapy, (7) genotype 2,
(8) low platelet count, (9) low serum albumin concentration, (10)
the number of comorbid medical conditions, and (11) high acute
physiology and chronic health (APACHE) Π and Hilf ’s severity
scores on admission to ICU (21, 47–50).
CLINICAL COURSE IN PATIENTS WITH A. BAUMANNII BACTEREMIA
In patients with A. baumannii bacteremia, the overall mortality
rate ranges between 25 and 54% and mortality depends on a num-
ber of factors that include general clinical condition of the patient,
whether the patient is managed in general wards or in ICU and
whether the organism is susceptible or resistant to antimicrobial
Table 4 | Risk factors forA. baumanni i bacteremia.
(1) Immunosuppression
(2) Unscheduled admission to hospital
(3) Prior antimicrobial therapy
(4) Previous ICU sepsis
(5) Development of septicemia or septic shock
(6) Respiratory failure on admission to ICU
(7) Use of invasive procedures
(8) Endotracheal intubation and mechanical ventilation
(9) Recent insertion of a CVC
(10) Bacteremia caused by other microorganisms after colonization by
MDRAB
CVC, central venous catheter; MDRAB, multidrug resistant Acinetobacter bau-
mannii.
therapy (1, 3, 48, 49, 51, 52). Studies have shown that crude mor-
tality rate ranges between 5 and 16.3% outside ICU while in ICU,
it ranges from 34 to 70% and may even reach 91.7% in case the
organism is MDR. However, in critically ill patients, attributable
mortality toA. baumannii bacteremia ranges between 7.8 and 19%
(1, 3, 48, 49, 51, 52).
MDRAB BACTEREMIA
Risk factors for MDRAB bacteremia include: prior ICU admission
and prior use of broad-spectrum antibiotics, particularly car-
bapenems,β-lactams, and inhibitors of β-lactamases. Independent
risk factors for mortality in patients having MDRAB bacteremia
include high APACHE Π score and presence of secondary rather
than primary bacteremia (52). Septic shock has been reported
in 42% of patients having A. baumannii bloodstream infections.
Complicated clinical course and life-threatening complications are
more likely to evolve in immunocompromised individuals (3). In
patients with A. baumannii bacteremia, good prognosis is asso-
ciated with infections related to CVCs where survival may reach
96.2% while poor outcome is associated with inappropriate uti-
lization of antimicrobial therapy and presence of respiratory tract
infections where mortality rate may reach 39.2% (48, 50). Sources
of A. baumannii bacteremia in ICU settings include primary bac-
teremia, respiratory tract, wounds, and intravascular catheters
(47). Risk factors forA. baumannii in ICU patients include invasive
procedures, use of broad-spectrum antimicrobials, and the critical
condition of the patient i.e., immunosuppression and comorbid
medical conditions. In ICU patients,A. baumannii bacteremia car-
ries a high mortality rate and although imipenem is active against
A. baumannii infections, the increasing resistance to carbapenems,
particularly in ICU setting, is alarming (47).
Sequential organ failure assessment (SOFA) and APACHE
scores determined at the onset of A. baumannii bacteremia are
reliable risk stratification tools that predict 14-day and in-hospital
mortality (3). The invasive procedure index, the number of inva-
sive procedures performed everyday during the ICU stay before
the onset of A. baumannii bacteremia divided by the number
of days spent in the ICU before the onset of A. baumannii bac-
teremia, is also important in determining the outcome of patients
having bacteremia (46). Early identification of patients at high
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risk of mortality based on a variety of risk factors is impor-
tant. Consequently, treatment strategies should be based on risk
stratification of patients having A. baumannii bacteremia (50).
TREATMENT OF A. BAUMANNII BACTEREMIA
The treatment of choice for A. baumannii bacteremia is not yet
established. In patients having infected CVCs, removal of these
catheters is indicated (48). Concerns have been raised about the
use of tigecycline is treating A. baumannii bloodstream infections
thus leaving colistin as the only therapeutic option for some of
these infections (1).
ACINETOBACTER BAUMANNII BACTEREMIA IN HSCT RECIPIENTS
In recipients of HSCT, the risk factors for the development of
A. baumannii bacteremia include: (1) severe underlying illness
such as hematologic malignancy, (2) immunosuppressive thera-
pies such as corticosteroids and cyclosporine-A, (3) graft versus
host disease (GVHD), (4) colonization of respiratory, gastroin-
testinal, and urinary tracts, (5) prolonged use of broad-spectrum
antibiotics, and (6) invasive instrumentation such as CVCs and
endotracheal intubation (3, 53). In a single center retrospective
study that included 483 HSCT recipients and performed over
6 years, 19 patients developed MDRAB bacteremia after engraft-
ment, pneumonia was the origin of bacteremia in all patients and
95% of patients with bacteremia and 8.3% of patients without
bacteremia died. The risk factors for the development of MDRAB
bacteremia in HSCT recipients were history of care in ICU after
HSCT and the time duration between admission to hospital and
HSCT (53).
NOVEL THERAPIES FOR A. BAUMANNII INFECTIONS
The global emergence of MDRAB necessitates the development of
novel preventive and therapeutic strategies to control infections
caused by this pathogen. Recently, there has been increased inter-
est in non-antibiotic approaches that utilize novel mechanisms of
action to achieve antibacterial activity (54). Recent advances in
the following potential therapeutic modalities have shown activity
against A. baumannii: (1) phage therapy, (2) iron chelation treat-
ment, (3) antimicrobial peptides, (4) prophylactic vaccination, (5)
photodynamic peptides, (6) decontamination with hydrogen per-
oxide, and (7) nitrous oxide-based therapies (54–57). However,
these therapeutic approaches have their own limitations and long-
term safety must be addressed before utilization of these novel
therapies in the clinical arena (54).
Phages have been used as pharmaceutical agents for more
than 90 years. Evolution of MDR bacterial infections has renewed
interest in the utilization of living phages in the treatment of
infectious diseases in humans and animals (55). The develop-
ment of a phage cocktails therapy, such as phage Φm18p, could
be an alternative therapeutic modality to antibiotics in the man-
agement of life-threatening bacterial infections in the future (55).
The novel lipoglycopeptide [telavancin] has shown remarkable
synergistic activity once combined with polymyxins, such as col-
istin, in the treatment of GNB infections including those caused
by MDRAB (56). Therefore, glycopeptide–polymyxin combina-
tions may become a useful therapeutic option in the treatment of
infections caused by MDR–GNB (56).
Currently, colistin and tigecycline are the drugs of choice for
MDRAB infections. However, these drugs have their own limita-
tions, side effects in addition to the potential of development of
drug resistance (55, 58). Colistin and intravenous colistimethate
sodium are peptide antibiotics that can be used as a last-resort
treatment of infections caused by MDRAB (58).
Comprehensive infection control measures, combined with
environmental decontamination using vaporized hydrogen per-
oxide, can interrupt the cycle of transmission of MDRAB within
long-term acute health care facilities (57). Silver carbene com-
plexes and their nanoparticles have shown activity against clinical
isolates of several MDR bacteria including A. baumannii (59).
Their low toxicity and increased antimicrobial activity against a
multitude of virulent pathogens facilitates their future applica-
tion as potential targeted therapies for serious infections caused
by MDR bacteria (59).
AntibacTR is a computation pipeline composed of a database
and web-based tool for ranking of proteins present in GNB. It aids
researcher working in the field of antibacterial drug discovery to
select potential drug targets (60). It is versatile and integrates both
experimental annovation and computational analysis. Currently,
the database covers 74 GNB including A. baumannii (60).
DONOR GRANULOCYTE TRANSFUSION THERAPY
Antibiotic refractory bacterial infections and opportunistic fun-
gal infections are important causes of morbidity and mortal-
ity in neutropenic patients (61). Polymorphonuclear leukocytes
(DMNLs) play a vital role in host defense against various infectious
agents (61). The relationship between the degree and duration of
neutropenia and the risk of infections had been observed since
the 1960s (62). However, the efficacy and feasibility of donor
granulocyte transfusion therapy (GTX) has changed consider-
ably over the past five decades (63). Since the late 1990s, there
has been renewed interest due to the increasing demand for
GTX following several reports of efficacy of this procedure to
treat and prevent severe infections in patients with neutrope-
nia (64, 65). Despite the lack of solid evidence, GTXs are con-
sistently used as adjunctive therapy of severe, persistent, and
progressive infections in neutropenic individuals (62, 65, 66).
Response rates ranging between 30 and 83% have been observed
in neutropenic patients with severe and uncontrolled infections
but overall survival was mostly determined by the underlying
disease process and the time of endogenous neutrophil recov-
ery (62, 66). Bacterial infections consistently responded bet-
ter than fungal infections and patients having GN organisms
responded better than those having Gram-positive bacterial infec-
tions (62, 65). GTXs and granulocyte stimulating factors have
successfully been used as adjunctive therapies in patients with
severe aplastic anemia (SAA) having serious bacterial and fungal
infections (67–69).
Despite the presence of multiple predictors of increased mor-
tality in cancer patients with candidemia, high-dose GTXs in these
high-risk patients has been associated with better than expected
survival rates (63). GTXs have also been used prophylactically in
neutropenic patients despite the absence of solid evidence to sup-
port pre-emptive utilization of donor GTXs (62, 70). However,
results of the few published studies reported positive outcome but
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no significant difference with respect to duration of hospitalization
or 100-day survival has been reported (62, 70).
Despite numerous clinical trials on the use of GTXs in treat-
ing bacterial and fungal infections in neutropenic patients, the
safety and efficacy of this potential therapeutic modality remain
controversial (61, 71). Therefore, there is a need for controlled
prospective trials to evaluate the best time to give donor GTXs,
the role of donor granulocytes as pre-emptive-empiric therapy
and the optimal duration of adjunctive high-dose GTX in selected
high-risk patients having systemic infections (63).
The following minimal criteria are usually used to justify the use
of donor GTXs: (1) absolute neutrophil count 500× 109/L except
in case of chronic granulomatous disease, (2) evidence of bacterial
or fungal infection: clinical symptoms of infection, positive cul-
tures, pathological diagnosis of infection made by biopsies taken
from involved sites, and radiological evidence of infection such
pneumonia, and (3) unresponsiveness to antimicrobial therapy for
at least 48 h except in extreme circumstances with life-threatening
infections (72, 73).
Two major non-randomized trials on the use of donor GTXs
have been published. The first one, phase I/II trial in neutropenic
patients with severe infections included 30 patients, whose infec-
tions had not been controlled with adequate antibiotics and G-CSF
administration. Following granulocyte transfusions: bacterial and
fungal infections were controlled in 82 and 38% of patients, respec-
tively and 100-day survival in patients having bacterial and fungal
infections were 82 and 54%, respectively (72, 74). The second one,
phase I/II non-randomized trial, showed that resolution of infec-
tion occurred in 8 of 11 patients with invasive bacterial and fungal
infections and that 50% of patients who received GTXs follow-
ing HSCT survived until engraftment. However, none of the five
patients with invasive aspergillosis cleared the infection, but no
evidence of infection was found at autopsy (72, 75).
A Cochrane meta-analysis of eight randomized clinical trials on
the use of donor GTXs in neutropenic patients concluded that the
available evidence was insufficient to either support or refute the
generalized use of GTXs in the most common neutropenic patient
populations i.e., patients receiving myeloablative chemotherapy
and/or HSCT (72, 76).
The national heart, lung, and blood institute (NHLBI) has
recently sponsored a large multicenter, phase III randomized clin-
ical trial (the RING study: resolving infections in people with
neutropenia using high-dose granulocyte transfusions), with the
aim to evaluate the incremental benefits of donor GTXs in patients
having bacterial and fungal infections post-HSCT (62, 67, 72). The
study has already finished accrual and the results are awaited. The
results of this clinical trial are expected to have a great impact on
the use of GTXs in neutropenic patients having severe fungal and
bacterial infections (62, 67, 72).
Until the results of prospective randomized controlled trials
including the RING study are available, the use of donor GTXs
in patients with bone marrow failure, hematological malignancies
and in recipients of HSCT having septic neutropenia or serious
bacterial and fungal infections will continue (67, 72). However,
GTXs should be given in specific institutions according to well
established and preferably standardized operational procedures in
order to ensure safety of both donors and recipients (62).
Complications of GTXs in recipients include: (1) allergic reac-
tions such as fever and hypotension, (2) pulmonary complications
such as respiratory distress, pulmonary infiltrates, pulmonary
edema, and transfusion-related acute lung injury, (3) transfusion-
related GVHD due to presence of donor lymphocytes in gran-
ulocyte concentrates, (4) alloimmunization due to formation of
HLA antibodies directed against granulocyte-specific antigen, and
(5) transmission of infectious agents such as cytomegalovirus
(CMV) which is harbored in peripheral blood leukocytes (61,
62, 65, 66, 72).
In recipient of HSCT having donor GTXs, the main concerns
are: (1) GVHD which is a potential complication of granulocyte
transfusion, (2) alloimmunization and formation of HLA anti-
bodies directed against granulocyte-specific antigen (61, 66, 72),
and (3) the effect of transfusion-associated leukocyte compati-
bility on the clinical outcome of HSCT (61). Patients, who had
previously received GTX from incompatible donors, experienced
delayed PMNL engraftment and more febrile episodes following
HSCT (61). In neutropenic HSCT recipients, serial granulocyte
transfusions have been successfully used in the treatment of MDR
bacterial infections causing septic complications (77). In recipi-
ents of HSCT having invasive fungal infections, GTXs have also
been successfully used in combination with antifungal agents to
control these serious infections (78, 79).
Allogeneic HSCT recipients have defects involving different
components of their immune system which subsequently increase
the risk of having invasive fungal infections (80). Neutropenia
is the single most important risk factor for the development of
invasive fungal infections in recipients of HSCT (80). One of the
potential approaches that aid in restoration of immunity and help
in fighting fungal infections is the administration of granulocytes
that have donor-derived antifungal T-cells (80, 81).
CONCLUSION
Acinetobacter baumannii has recently emerged as a major cause
of morbidity and mortality in hospitalized immunocompromised
individuals. Increasingly reported drug resistance exhibited by the
organism is gaining global dimensions and complicates the man-
agement of infections caused by this GNB. Patients with hemato-
logical malignancy and recipients of various types of HSCT are at
high risk for development of infectious complications related toA.
baumannii. Appropriate utilization of antimicrobials, provision of
advanced supportive care, and application of strict infection con-
trol measures are essential in the management of infections caused
by A. baumannii.
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